MDNAF Projected Dividend Yield

Medicenna Therapeutics Corp ( OTCBB : MDNAF )

Medicenna Therapeutics is an immunotherapy company developing interleukin-2, interleukin-4 and interleukin-13 tunable cytokines, called Superkines. These Superkines can be developed either on their own as short or long-acting therapeutics or fused with cell killing proteins in order to generate Empowered Superkines that deliver potent toxins to cancer cells. Superkines can also be fused with proteins, antibodies and other Superkines in order to incorporate two synergistic therapeutic activities into one molecule, creating Bi-Functional SuperKine ImmunoTherapies referred by Medicenna as BiSKITs™. Co.'s Product Candidate, MDNA55, is used for the treatment of tumors of the brain in adults.

20 YEAR PERFORMANCE RESULTS